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ABSTRACT 
 
 
Aims: Heart failure with preserved and mid-range ejection fraction (HFPEF, HFmrEF) are becoming 
the most prevalent forms of HF. Patients with HFPEF/ HFmrEF in atrial fibrillation (AF) have poorer 
survival and quality of life, however the mechanism underpinning this is unknown. We sought to 
investigate the influence of AF on the hemodynamic profile of HFPEF/ HFmrEF patients at rest and 
during exercise. 
 
Methods and Results: We invasively measured central hemodynamics at rest and during symptom 
limited supine bicycle exercise in HFPEF/ HFmrEF patients, 35 in sinus rhythm and 20 in AF with 
matched LVEF. At rest, AF patients had significantly increased pulmonary capillary wedge pressures, 
lower cardiac index and reduced left ventricular stroke work index, despite similar resting heart rate. 
Under resting conditions, the calculated oxygen consumption and systemic arteriovenous oxygen 
gradient was not different between the two groups. During supine cycling at similar levels of workload, 
AF patients exhibited a reduced capacity to increase their oxygen consumption and this was 
accompanied by a persistently impaired cardiac index and LV stroke work index.  
 
Conclusions: The adverse interaction of AF and HFPEF/HFmrEF may be accounted for by an 
adverse impact on LV systolic function and peripheral oxygen kinetics. 
 
 
 
Key words: heart failure with preserved ejection fraction; atrial fibrillation; hemodynamics; systolic 
function  
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Introduction 
 
Patients with clinical features of heart failure in the setting of HFPEF or HFmrEF are an increasingly 
common component of the overall burden of HF (1, 2). These patients typically experience a similar 
degree of functional limitation as those with HFREF (3, 4). Furthermore, mortality rates and the 
requirement for hospitalization are roughly similarly for HFPEF and HFREF patients. Despite the clear 
need for effective therapy, only modest progress has been made in regard to the development of 
proven therapies in HFPEF or the recently defined HFmrEF. Specifically, no treatment to date has 
been shown to improve survival, whilst there is only limited evidence for pharmacologic approaches to 
reduce hospitalization (5, 6). 
 
One potential explanation for the lack of success in HFPEF trials is the considerable variability in the 
clinical features of HFPEF patients and in their co-morbidities (7, 8). In particular, patients tend to be 
older, more overweight, diabetic and have a history of hypertension and renal disease. Each of these 
factors may modify the signs and symptoms of HF, whilst also influencing echocardiographic 
parameters and circulating biomarker levels.  
 
A history of prevalent or incident atrial fibrillation is also particularly common in HFPEF (1, 9-11). It is 
evident that patients with AF and HFPEF experience poorer outcomes than those in SR (12, 13). 
Whilst the presence of an adverse effect of AF has also been reported in HFREF, it appears that the 
modifying effect is even greater in HFPEF (12, 13). It has been previously shown that patients with 
HFPEF and AF are more symptomatic and have a lower peak VO2 than those in SR, although the 
hemodynamic basis has not been determined during physical activity (14, 15). Despite this important 
observation, the precise mechanism for the adverse relationship between AF and HFPEF remains 
unknown. Previously we demonstrated that an irregular rhythm per se was associated with adverse 
myocardial molecular remodeling in HFREF, with attendant implications for contractile performance 
(16). In the current study we hypothesized similar processes might be operative in HFPEF/HFmrEF 
patients in AF. We therefore compared the central hemodynamic profiles of HFPEF/HFmrEF patients 
in AF to those in SR, with particular emphasis on the hemodynamic response to exertion.  
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Methods 
 
Study Design and Patient population 
The present study represents a retrospective, post-hoc analysis of the hemodynamic features of a 
cohort of patients with confirmed HFPEF or HFmrEF. Baseline study data was obtained from subjects 
who were participating in a trial of a novel inter-atrial septal device, described elsewhere in detail (17, 
18). In brief, study inclusion criteria included a history of chronic symptomatic HF (NYHA class II-IV), 
a left ventricular ejection fraction >40% and by definition patients had to have an elevated pulmonary 
capillary wedge pressure (PCWP) at rest (>15mmHg) or during exercise (>25mmHg), as described 
below. Natriuretic peptide levels were not used as an entry criteria. Subjects had to be able to perform 
supine cycle ergometry as described below. For the current study we included patients with resting 
LVEF within the range 40-60% to avoid the potential confounding effects of significant between group 
differences in LVEF. Data included in the current study comprise the baseline data collected prior to 
device implantation. All subjects gave written informed consent and the study was approved by 
relevant institutional ethics committees. 
 
Right Heart Catheterization  
After meeting non-invasive inclusion criteria, patients underwent right heart catheterization for the 
measurement of cardiac output and hemodynamic pressures at rest and during supine bicycle 
exercise. After the completion of baseline measurements, patients were instructed to perform 
symptom-limited exercise commencing at 20 Watts (W) with 20W increments every 3 minutes until 
symptom-limiting maximal effort was reached. Mixed venous blood gas samples were collected at rest 
and at peak exercise for the calculation of arteriovenous oxygen difference and oxygen consumption 
(VO2) with the use of the thermodilution cardiac output and indirect oximetric assessment of the 
arterial oxygen saturation. Hemodynamic traces were evaluated at an independent core laboratory 
(PV Loops LLC, NY, USA) for the measurement of right atrial, pulmonary arterial and PCWP at rest 
and peak exercise. PCWP and pulmonary artery pressure were also recorded at 20W. 
 
Hemodynamic and Metabolic Calculations 
Systemic and mixed venous oxygen content was determined according to standard formulae and the 
arteriovenous oxygen content difference was subsequently calculated. Oxygen consumption (VO2) 
was calculated as the product of the average cardiac output (measured by thermodilution method) 
and the arteriovenous oxygen difference at rest and exercise respectively. We did not perform 
concurrent expiratory gas analysis for direct Fick analysis of cardiac output.  Stroke volume index 
(SVI) was calculated from the ratio of the cardiac index to heart rate. Left ventricular stroke work index 
was calculated according to the formula: LVSWI = (MAP-PCWP) x SVI x 0.0136. Right ventricular 
stroke work index was calculated according to the formula: RVSWI = (MPAP-CVP) x SVI x 0.0136. 
Systemic and pulmonary vascular resistance were calculated according to standard formulae. The 
systemic arterial elastance (Ea) was calculated according to the formula: Ea= ESP/SV, where ESP 
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was calculated as 0.9xMAP. Pulmonary arterial compliance was calculated as PAC = SV/(PAsys-
PAdias). 
 
 
 
Echocardiography 
Echocardiographic images were obtained by trained research echocardiographers at each study site, 
and the analysis was performed at an independent core laboratory located at the University of 
Pennsylvania (PA, USA). Echocardiographic measurements were made according to published 
guidelines (19). Offline analysis included measurement of left ventricular and left atrial volumes, right 
atrial and ventricular volumes and the tricuspid annular plane systolic excursion. 
  
Statistical Analysis 
Data are presented as mean±standard error of the mean, median (25
th
-75
th
 percentile range) or as 
count according to the distribution of the variable. Between group analyses were conducted using n t-
test, Chi square test or Wilcoxon rank-sum test where appropriate. Differential responses to exercise 
between groups were investigated by repeated measures ANOVA, including an evaluation of the 
exercise x rhythm interaction term. A p value of <0.05 was considered to be statistically significant. 
Statistical analysis was performed using a commercially available software package (IBM SPSS 
Statistics version 22, SPSS Inc, Chicago, Illinois). 
 
Results 
 
The current study compared the demographic, echocardiographic and hemodynamic features of a 
cohort of HFPEF patients dichotomized according to the presence of SR or AF. As shown in Table 1, 
HFPEF patients in SR (n=35) were similar to those in AF (n=20) with regard to age, BMI, gender 
distribution and left ventricular end diastolic volume and LVEF (Table 2). The left atrial volume index 
was considerably larger in AF patients (AF vs SR: 433 vs 303 ml/m
2
, p=0.005), as was the right 
atrial volume index (AF vs SR: 424 vs 323 ml, p=0.03), as shown in Table 2. Right ventricular 
function as reflected by the tricuspid annular plane systolic excursion was lower in AF patients (AF vs 
SR: 171 vs 211 mm, p=0.004). NT-proBNP was significantly higher in AF patients. Across the 
entire cohort, NT-proBNP and log NT-proBNP levels were inversely correlated with cardiac output (r= 
-0.31, p=0.03 and r= -0.34, p=0.02 respectively). By analysis of covariance, natriuretic peptide levels 
continued to differ significantly between rhythm groups (p<0.001).  
 
Baseline Hemodynamics and Metabolism 
At rest, the heart rate and systemic blood pressure were similar in SR and AF patients (Table 3). By 
contrast, the resting pulmonary PCWP and mean PA pressures were significantly higher in patients 
with AF. In conjunction, the resting cardiac index was lower in patients with AF as compared to SR 
patients (AF vs SR: 2.50.1 vs 2.90.1 ml, p=0.038). This difference was accounted for by a 
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significantly lower stroke volume index in patients in AF. Accordingly the LVSWI was lower at rest in 
AF patients (Table 3). At rest the arterial and mixed venous oxygen content were similar, and the 
calculated VO2 was similar between AF and SR patients at rest (AF vs SR: 3.00.1 vs 3.00.1 
mL/kg/min).  
 
In addition to differences in cardiac performance and right heart pressures, there was also evidence 
of differences in baseline vascular function between the two groups. At rest, the systemic vascular 
resistance in AF was similar to SR (18.81.3 vs 16.40.8 dyne.cm.sec
-5
) and the arterial elastance 
was also similar between patients groups (AF vs SR: 1.90.1 vs 1.60.1 mmHg/mL, p=ns). The 
resting pulmonary vascular compliance was lower in AF patients, consistent with a stiffer pulmonary 
circulation (SR vs AF: 3.70.3 vs 5.10.4 mL/mmHg, p=0.002). The pulmonary vascular resistance 
tended to be higher in AF patients (1.50.1 vs 1.10.1 mmHg.min/L) , p=0.05). 
 
Effect of Rhythm on Exercise Capacity and Hemodynamics 
At symptom limited peak exercise the calculated VO2 was significantly lower in AF patients compared 
to SR patients (AF vs SR: 6.20.7 vs 9.70.6 mL/kg/min, p=0.003, Table 4). Furthermore, whilst as 
expected exercise significantly increased VO2 across the entire cohort, the VO2 response to exercise 
was significantly blunted in AF patients as demonstrated in Figure 1, despite a similar heart rate and 
systemic blood pressure response. Right atrial, pulmonary artery and pulmonary capillary wedge 
pressures all rose significantly (p<0.001). At peak exercise the right atrial pressure was significantly 
higher in AF patients. 
 
During exercise cardiac index rose significantly in both SR and AF groups (both p<0.001), however 
the magnitude of the rise in cardiac index during exercise was significantly blunted in AF patients as 
compared to that in SR (Figure 2A and B).  The lower peak cardiac index in AF patients was 
principally explained by a significantly lower peak stroke volume index, although the magnitude of the 
exercise mediated change did not differ statistically between patient groups (Figure 2C and D). In 
keeping with the cardiac index responses, left ventricular stroke work index (LVSWI) was also 
significantly lower in AF at rest and at peak exercise (Figure 2E and F). Together with between group 
differences in cardiac performance, we also identified a differential oxygen extraction response 
between groups. As shown in Figure 2G and H, whilst the AVO2 difference increased with exercise, 
the magnitude was significantly less in AF patients. 
 
Given that TAPSE was lower in AF patients we also evaluated hemodynamic measures of RV 
performance. RVSWI was not different between SR and AF at rest (Table 3), whilst it was lower in AF 
patients during exercise (Table 4). At rest there was a modest correlation between LVSWI and 
RVSWI (r=0.036, p=0.008) and the correlation was more evident during exercise (r=0.54, p<0.001). 
There are no differences between the TAPSE groups in hemodynamic or metabolic parameters at 
rest (Supplementary Table 3). During exercise there were no differences in the exercise time or peak 
workload. There were no significant differences between the groups with respect to stroke volume 
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index or cardiac index during exercise (Supplementary Table 4), whilst the right atrial pressure was 
significantly greater in the low TAPSE group (20±1 vs 17±1, p=0.046) and the calculated VO2 was 
somewhat lower (7.30.7 vs 9.10.8ml/kg/min, p=0.018). Of note the magnitude of the differences in 
these parameters was less than that when patients were stratified according to the presence or 
absence of AF. 
 
.  
Discussion  
We compared the hemodynamic profiles of HFPEF patients in AF to those in SR to understand the 
basis for the adverse impact of AF on outcomes. Patients were similar in regard to their degree of 
symptomatic and functional limitation together with their LVEF. In addition, patients were well 
matched with regard to comorbidities and concomitant medications, except for digoxin.  We 
demonstrated that at rest, HFPEF patients in AF had evidence of increased filling pressures, lower 
cardiac index and reduced left ventricular stroke work index, despite similar resting heart rate. AF 
patients also had significantly greater left and right atrial volumes compared to SR patients. NT-
proBNP levels were significantly higher in AF patients. Under resting conditions, the calculated 
oxygen consumption and arteriovenous oxygen gradient was not different between the two groups. 
During supine cycling at similar levels of workload, AF patients exhibited a reduced capacity to 
increase their oxygen consumption and this was accompanied by a persistently impaired cardiac 
index and LV stroke work index. 
 
Impaired diastolic reserve has been identified as playing an important role in the causation of HFPEF 
symptoms based upon the demonstration of raised filling pressures, particularly during exertion (20-
22). Mechanistically, myocardial fibrosis has been well documented in HFPEF on the basis of 
myocardial biopsy and magnetic resonance imaging (MRI) (23-25). In the context of the current study, 
MRI studies have also demonstrated the presence of increased levels of ventricular fibrosis in 
patients with AF compared with controls (26, 27). The finding of elevated filling pressures in AF 
patients with similar left ventricular diastolic volumes would be consistent with more advanced 
myocardial fibrosis. During exercise, patients reached similar peak filling pressures as measured by 
the pulmonary capillary wedge pressure. It is possible that between group differences could have 
been missed given the limitations of PCWP measurement to estimated LVEDP during exercise. 
Additionally, we did not measure LV diastolic volumes during exercise thus precluding the possibility 
that differences in LV volumes may have been present.  
 
Together with the effects of myocardial fibrosis, diastole performance is also dependent upon early 
active relaxation and factors that operate throughout diastole. The initial phase of active relaxation 
can be adversely influenced by ischemia and increased late systolic afterload (28). In the current 
study, AF patients had a somewhat higher arterial elastance at rest, which could possibly have 
influenced diastolic performance although this difference was not significant during exertion. Titin and 
its phosphorylation state is increasingly recognized as a key modifier of diastolic stiffness (29, 30), 
however the effect of AF on titin phosphorylation is unclear. 
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In the current study, LA enlargement was evident in AF patients consistent with prior reports (31). The 
precise contribution of LA contractility to cardiac output is not known in HFPEF, although it has been 
estimated that the LAEF is approximately 40% (32). Under acute conditions, left atrial mechanical 
function contributes significantly to left ventricular filling and to pulmonary venous and arterial 
pressures, via its compliance properties and contractility (33). Impaired atrial function could explain 
the reduction in resting cardiac output in AF patients, however interestingly the degree of 
augmentation in LV stroke volume during exercise was similar in both groups suggesting that the LA 
may be relatively passive in the exercise cardiac output response. This conclusion is consistent with 
the data of Melenovsky and colleagues who demonstrated the presence of a relatively flat relationship 
between atrial preload and stroke volume in HFPEF (32).  Further, this suggests that the rise in LA 
pressure during exercise is a reflection of atrial compliance together with ventricular diastolic function.  
 
Despite similar, or greater LV filling pressures, we found that AF patients had evidence of reduced 
systolic function as reflected by a lower stroke work index during both rest and exercise. Reduced LV 
systolic function, assessed by strain imaging, has been demonstrated to be an important prognostic 
factor in HFPEF (34). An adverse interaction between AF and HFREF has also been identified (35-
37), and it has been suggested that irregular cycle length per se rather than loss of atrial function or 
inadequate rate control may be an important factor (36, 38-40). In this context, we showed that 
patients with advanced HFREF and AF had reduced ventricular expression of the sarcoplasmic 
reticulum ATPase (SERCA2a) and a reduction in the extent of phospholamban phosphorylation (16). 
Further, we previously showed that isolated cardiomyocytes paced electrically with an irregular drive 
sequence similarly exhibit reductions in SERCA2a expression and in the degree of phosphorylation of 
phospholamban (16). Given the evidence of impaired LV systolic function in the present study, it is 
possible that molecular changes such as these could occur in HFPEF patients in AF.  
 
In addition to left ventricular systolic dysfunction, AF patients also demonstrated some evidence of 
right ventricular systolic dysfunction as reflected by the lower resting TAPSE. The presence of RV 
dysfunction in HFPEF is well described (41) and has been shown to be associated with poorer 
outcome. RV dysfunction in HFPEF is typically considered to be the consequence of exposure to 
pulmonary hypertension. Recent studies have investigated the potential utility of phosphodiesterase 
type V inhibitors in HFPEF patients. These agents have not yielded benefit in HFPEF (42, 43), 
however the studies were not designed to investigate potential utility in subgroups such as those with 
AF.  At rest in the present study AF patients did have modest, but significantly higher pulmonary 
artery pressures together with evidence of elevated pulmonary arterial stiffness. It is also possible that 
an irregular rhythm contributed to the reduction in RV systolic function in a similar manner to the LV. 
Consistent with this, there were significant correlations between RV and LVSWI at rest and during 
exercise. Interestingly TAPSE per se did not distinguish for the presence of greater degrees of LV or 
RV dysfunction. 
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The 33% reduction in peak O2 consumption, calculated via the Fick equation, in AF patients was 
accounted for by a 19% reduction in cardiac output in conjunction with a 17% reduction in the AVO2 
difference.  At rest the AVO2 difference was similar amongst groups, despite a somewhat lower 
cardiac index. During exercise, at similar albeit low workloads, the mixed venous oxygen context was 
significantly lower in SR patients suggesting greater muscle extraction of oxygen. This finding is also 
somewhat surprising given that the cardiac output in AF patients was lower during exertion, which 
would be expected to result in a lower mixed venous oxygen content. The AVO2 difference principally 
reflects net effect of peripheral O2 consumption together with extraction which is influenced by transit 
time and the diffusional coefficient (44). Whilst interpretation of the current data is limited by difficulty 
in ensuring a true steady state, the data suggest that oxygen delivery to muscle could become limiting 
in AF patients leading to an inability to increase oxygen extraction. Alternately a substantial difference 
in muscle mass could account for the findings, although body weight and work capacity were similar 
between groups. Abnormal large and small vessel function, ventriculo-vascular coupling and skeletal 
muscle performance is also a determinant of functional capacity in HFPEF. AF patients demonstrated 
features of increased arterial elastance at rest indicating the possibility that there was a concomitant 
abnormality of vascular function. The specific mechanism for abnormal arterial function in AF patients 
could not be determined from the current study. AF patients were slightly older, but otherwise had 
similar mean blood pressure and BMI. The true direct physiologic effect of AF in comparison to its 
possible role as a marker of chronicity or severity can only be addressed by repeating the 
hemodynamic evaluation after reversion to SR. 
    
Our finding of an increased NT-proBNP level in AF patients is consistent with other studies in both 
HFREF and HFPEF (ref). We observed a modest inverse correlation with cardiac output, however this 
did not account for the between group differences in natriuretic peptide levels. Previously, we 
demonstrated that myocardial release rates of natriuretic peptides are related to LV systolic wall 
stress (45). The effect of varying cycle lengths on local wall stress are not known. Plasma levels of 
NT-proBNP are also influenced by other factors such as renal function and obesity, however in the 
present study eGFR and BMI did not differ significantly between groups. Recent studies have raised 
questions regarding the sensitivity and specificity of resting measures, including natriuretic peptide 
levels, for the diagnosis of HFPEF (46). In the current study, natriuretic peptide levels were not an 
entry criteria for study inclusion, and 7 patients in the SR group had NT-BNP levels <100pg/mL. To 
account for this as a potential confounder we conducted a further comparison of rest and exercise 
hemodynamics when excluding patients with low NT-BNP levels. As shown in Supplementary Tables 
1 and 2, the blunted VO2, cardiac index and stroke volume index remained evident during exertion in 
AF patients.  
 
The limited success of prior trials in HFPEF has been attributed to a range of issues, including 
difficulties with the identification of homogeneous sub-populations with sufficient and consistent event 
rates. As recently reviewed, AF has been identified in between 21 and 34% of HFPEF registry 
patients and from 4 to 61% of trial patients (5). Our data indicate that AF patients exhibit 
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hemodynamic differences to SR patients that could respond differently to various interventions. As 
noted above, AF patients had higher NT-proBNP levels, larger left atrial volumes and a lower peak 
VO2, which are all known to be independently associated with a worse outcome in HFPEF (47). 
Accordingly, the current data further underscore the need for careful consideration of clinical trial 
design and the balanced inclusion of AF patients in HFPEF studies. 
 
The current study has some potential limitations. We did not investigate whether reversion to SR 
improved hemodynamics in the AF group, and as such the present data provide evidence for an 
association between AF and hemodynamic impairment. For pragmatic and safety reasons, patients 
performed symptom limited exercise in the supine position rather than the upright position. It is 
possible that differences in venous return may result in findings that vary between the supine position 
and the upright position. Also we did not require patients to work to a pre-determined or estimated 
peak exercise capacity and we did not perform respiratory gas analysis during the exercise right heart 
catheter study.  
 
Taken together, this study highlights the presence of important differences in the central 
hemodynamic and peripheral responses of HFPEF patients in AF during exercise. These 
observations, particularly in respect of relative impairments in left and right ventricular systolic function 
in AF could explain previously reported differences in clinical outcome according to rhythm. Detailed 
physiologic and molecular studies may provide further insights into the effect of AF on myocardial 
biology. 
 
 
FIGURE LEGENDS: 
Figure 1: Graph representing the differential capacity to increase oxygen consumption during exercise  
in HFPEF patients in SR vs AF. 
 
Figure 2. Graphs comparing rest and exercise values together with the magnitude of the exercise 
induced changes for A,B cardiac index; C,D stroke volume index; E,F left ventricular stroke work 
index; and G,H arterio-venous oxygen difference in  SR vs AF patients. * p<0.05, **p<0.01. 
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Table 1. Baseline Clinical and Biochemical Characteristics 
Parameter Sinus Rhythm 
(n=35) 
Atrial Fibrillation 
(n=20) 
p value 
Age (years) 702 691 ns 
BMI (kg/m
2
) 331 311 ns 
NYHA (II/III) 10/25 5/15 ns 
eGFR (ml/min/1.73m
2
) 644 574 ns 
Medications (%)    
Diuretics 83 100 ns 
ACEI/ARB 83 70 ns 
Beta blockers 63 65 ns 
MR antagonists 43 45 ns 
Digoxin 3 35 <0.01 
Co-Morbidities (%)    
COPD 6 10 ns 
Diabetes 31 20 ns 
Chronic Kidney Disease 34 40 ns 
Hypertension 77 85 ns 
Myocardial Infarction 11 10 ns 
NT-BNP (pg/mL)* 272 (103-518) 1250 (719-1703) <0.001 
Abbreviations/Definitions: ACEI/ARB- angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker; MR mineralocorticoid receptor; COPD – chronic obstructive pulmonary disease;  
Chronic Kidney Disease defined as eGFR <60ml/min/1.73m
2
. 
*Median (25
th
-75
th
 percentile)  
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Table 2. Baseline Echocardiographic Characteristics 
 
Parameter Sinus Rhythm 
(n=35) 
Atrial Fibrillation 
(n=20) 
p value 
LVEF (%) 481 461 ns 
LVEDVI (mL) 1344 1376 ns 
LAVI (mL/m
2
) 303 433 0.005 
RAVI (mL/m
2
) 323 424 0.03 
TAPSE (mm) 2.10.1 1.70.1 0.004 
Abbreviations: LVEDVI left ventricular end diastolic volume index; LAVI left atrial volume index 
RAVI right atrial volume index; TAPSE tricuspid annular plane excursion. 
*Median (25
th
-75
th
 percentile)  
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Table 3. Resting hemodynamic and metabolic characteristics 
Parameter Sinus Rhythm 
(n=41) 
Atrial Fibrillation 
(n=23) 
p value 
HR (bpm) 672 724 ns 
MAP (mmHg) 952 983 ns 
SBP (mmHg) 1434 1435 ns 
RAP (mmHg) 91 101 ns 
PAm (mmHg) 221 271 0.015 
PAsys (mmHg) 352 412 ns 
PCWP (mmHg) 161 201 0.013 
TPG (mmHg) 61 71 ns 
CI (L/min/m
2
) 2.90.1 2.50.1 0.038 
SVI (ml/m
2
) 442 362 0.014 
PVR (mmHg.min/L) 1.10.1 1.50.1 0.05 
PA compliance (mL/mmHg) 5.10.4 3.70.3 0.01 
LVSWI (kg-m.min
-1
.m
-2
) 462 383 0.03 
RVSWI (kg-m.min
-1
.m
-2
) 8.40.9 8.70.8 ns 
CaO2 (mL/100mL) 17.00.4 17.30.5 ns 
CvO2 (mL/100mL) 12.10.4 12.10.5 ns 
C(a-v)O2 (mL/100mL) 4.80.2 5.20.2 ns 
VO2 (mL/min/kg) 3.00.1 3.00.1 ns 
Abbreviations: HR heart rate, MAP mean arterial pressure, SBP systolic blood pressure, 
RAP right atrial pressure, PAm mean pulmonary artery pressure, PAsys pulmonary artery 
systolic pressure, PCWP pulmonary capillary wedge pressure, TPG transpulmonary 
gradient, PVR pulmonary vascular resistance, CI cardiac index, SVI stroke volume index, 
LVSWI left ventricular stroke work index, CaO2, CvO2 arterial and mixed venous oxygen 
content, VO2 oxygen consumption. 
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Table 4. Exercise hemodynamic and metabolic characteristics 
Parameter Sinus Rhythm 
(n=41) 
Atrial Fibrillation 
(n=23) 
p value 
Peak Workload 473 394 ns 
Exercise time (min) 7.60.5 7.10.8 ns 
HR (bpm) 942 975 ns 
MAP (mmHg) 1164 1134 ns 
SBP (mmHg) 1755 1666 ns 
RAP (mmHg) 171 211 0.019 
PAm (mmHg) 432 472 ns 
PAsys (mmHg) 652 713 ns 
PCWP (mmHg) 341 361 ns 
TPG (mmHg) 91 101 ns 
CI (L/min/m
2
) 4.70.2 3.80.2 0.002 
SVI (ml/m
2
) 512 392 0.001 
PVR (mmHg.min/L) 1.00.1 1.50.2 0.03 
PA compliance (mL/mmHg) 3.30.3 2.60.4 ns 
LVSWI (kg-m.min
-1
.m
-2
) 563 425 0.02 
RVSWI (kg-m.min
-1
.m
-2
) 17.50.9 14.01.3 0.03 
CaO2 (mL/100mL) 16.60.5 17.20.5 ns 
CvO2 (mL/100mL) 7.70.5 9.80.7 0.018 
C(a-v)O2 (mL/100mL) 8.90.5 7.40.7 ns 
Ex-Rest C(a-v)O2 (mL/100mL) 4.10.6 2.10.7 0.03 
VO2 (mL/min/kg) 9.30.6 6.20.7 0.003 
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Figure 1 
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Figure 2 
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